915 related articles for article (PubMed ID: 27084761)
1. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
[TBL] [Abstract][Full Text] [Related]
2. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
[TBL] [Abstract][Full Text] [Related]
3. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis.
Punekar YS; Sharma S; Pahwa A; Takyar J; Naya I; Jones PW
Respir Res; 2017 May; 18(1):86. PubMed ID: 28482883
[TBL] [Abstract][Full Text] [Related]
4. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
[TBL] [Abstract][Full Text] [Related]
5. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
Luo J; Wang K; Liu D; Liang BM; Liu CT
Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
[TBL] [Abstract][Full Text] [Related]
6. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
7. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
8. Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
Donohue JF; Jones PW; Bartels C; Marvel J; D'Andrea P; Banerji D; Morris DG; Patalano F; Fogel R
Pulm Pharmacol Ther; 2018 Apr; 49():11-19. PubMed ID: 29277690
[TBL] [Abstract][Full Text] [Related]
9. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
10. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
11. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
[TBL] [Abstract][Full Text] [Related]
12. Exacerbation frequency and course of COPD.
Halpin DM; Decramer M; Celli B; Kesten S; Liu D; Tashkin DP
Int J Chron Obstruct Pulmon Dis; 2012; 7():653-61. PubMed ID: 23055714
[TBL] [Abstract][Full Text] [Related]
13. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
14. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.
Anzueto A; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2009; 4():245-51. PubMed ID: 19657398
[TBL] [Abstract][Full Text] [Related]
15. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.
Westwood M; Bourbeau J; Jones PW; Cerulli A; Capkun-Niggli G; Worthy G
Respir Res; 2011 Apr; 12(1):40. PubMed ID: 21477298
[TBL] [Abstract][Full Text] [Related]
16. The COPD assessment test and St George's Respiratory Questionnaire: are they equivalent in subjects with COPD?
Morishita-Katsu M; Nishimura K; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Ogawa T; Watanabe F; Arizono S; Nishiyama O; Nakayasu K; Imaizumi K; Hasegawa Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():1543-51. PubMed ID: 27462150
[TBL] [Abstract][Full Text] [Related]
17. Impact of preventing exacerbations on deterioration of health status in COPD.
Spencer S; Calverley PM; Burge PS; Jones PW
Eur Respir J; 2004 May; 23(5):698-702. PubMed ID: 15176682
[TBL] [Abstract][Full Text] [Related]
18. The St. George's Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition.
Kim V; Zhao H; Regan E; Han MK; Make BJ; Crapo JD; Jones PW; Curtis JL; Silverman EK; Criner GJ;
Chest; 2019 Oct; 156(4):685-695. PubMed ID: 31047955
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.
Zou Y; Xiao J; Yang DH; Li J; Chen Q
COPD; 2016 Aug; 13(4):499-508. PubMed ID: 26846588
[TBL] [Abstract][Full Text] [Related]
20. Impact of mild exacerbation on COPD symptoms in a Japanese cohort.
Sato M; Chubachi S; Sasaki M; Haraguchi M; Kameyama N; Tsutsumi A; Takahashi S; Nakamura H; Asano K; Betsuyaku T
Int J Chron Obstruct Pulmon Dis; 2016; 11():1269-78. PubMed ID: 27354785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
